ALLK (Allakos) Interest Expense : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Allakos Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Allakos's interest expense for the three months ended in Sep. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Allakos's Operating Income for the three months ended in Sep. 2024 was $ -19.75 Mil. Allakos's Interest Expense for the three months ended in Sep. 2024 was $ 0.00 Mil. GuruFocus does not calculate Allakos's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Allakos Interest Expense Historical Data

The historical data trend for Allakos's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Interest Expense Chart

Allakos Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

Allakos Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Allakos Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Allakos (NAS:ALLK) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Allakos's Interest Expense for the three months ended in Sep. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-19.75 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $35.71 Mil.

Allakos's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

GuruFocus does not calculate Allakos's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Allakos Inc has enough cash to cover all of its debt. Its financial situation is stable.

Allakos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (NAS:ALLK) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

37Z:Germany

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Executives

Harlan Baird Radford	officer: Chief Financial Officer	C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125
Graham Neil Murray Hamilton	director	33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Everett Rand Sutherland	director	29 HARTWELL AVENUE, LEXINGTON MA 02421
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Daniel Janney	director	PO BOX 7414, JACKSON WY 83002
Amy L Ladd	director	INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086
Craig A. Paterson	officer: Chief Medical Officer	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Margaret Nell Fitzgerald	officer: General Counsel and Secretary	ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Steven P James	director	C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Adam Tomasi	officer: COO, CFO and Secretary	ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Robert Alexander	director, officer: President and CEO	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Rasmussen Henrik S Md	officer: Chief Medical Officer	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
John P Mckearn	director, 10 percent owner	5820 NANCY DRIVE, SAN DIEGO CA 92121
Peter A Hudson	10 percent owner	701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067